Sanofi购买在大中国开发Aficamten(一种潜在的母国措施治疗)的权利,最高可达150万加元。 Sanofi buys rights to develop aficamten, a potential HCM treatment, in Greater China for up to $150M.

Sanofi从Corxel制药公司获得了开发并商业化Aficamten的专有权利,这是大中国高营养性心血管病(HCM)的潜在治疗方法。 Sanofi has acquired exclusive rights from Corxel Pharmaceuticals to develop and commercialize aficamten, a potential treatment for hypertrophic cardiomyopathy (HCM), in Greater China. Aficamten, 原由细胞动力学开发, 是一种心髓抑制剂。 Aficamten, originally developed by Cytokinetics, is a cardiac myosin inhibitor. Sanofi的收购包括可能达到1.5亿美元的里程碑付款和该区域销售费。 Sanofi's acquisition includes the potential for milestone payments of up to $150 million and royalties on sales in the region.